After gastrointestinal reconstruction surgery
Conditions
Interventions
Experimental group:The first initiation of parenteral nutrition supplemented with ?-3 triglycerides occurred between 24 and 48 hours postoperatively
Control group:The first initiation of parenteral nutrition supplemented with ?-3 triglycerides occurred between 48 and 72 hours postoperatively
Sponsors
The Second Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 80 years old, regardless of gender; (2) Diagnosed with gastric cancer, pancreatic cancer, lower bile duct cancer, or duodenal cancer by pathology, without distant metastasis, and scheduled to undergo gastrointestinal anastomosis (subtotal/total gastrectomy) or pancreatoduodenectomy. The surgery should be performed by a senior surgeon (associate chief physician or above), and the surgical approach can be robotic-assisted, laparoscopic, or open. (3)Expected to require parenteral nutrition support for =5 days postoperatively; (4) American Society of Anesthesiologists (ASA) physical status classification I-III; (5)The patient or their family member has signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Allergy to ?-3 triglycerides or other components of the medication (such as egg or soybean protein, peanut protein, or other ingredients in the prescription); (2) Presence of severe malnutrition (e.g., body mass index <18.5 kg/m², or serum albumin <30 g/L); (3) Contraindications for enteral nutrition; (4) Concurrent severe dysfunction of important organs such as the heart, liver, or kidneys; (5) Coagulation dysfunction; (6) Suffering from immune system diseases or undergoing immunosuppressive therapy, or having undergone splenectomy; (7) Pregnant or lactating women; (8) Patients with mental disorders or unable to cooperate with treatment and follow-up; (9) Presence of general intravenous infusion contraindications, electrolyte and fluid balance disorders, metabolic disorders (including protein metabolism disorders, lipid metabolism disorders, and hyperglycemia unresponsive to a 6-unit insulin/hour dose) during the screening period; (10) Occurrence of severe complications during surgery (such as hemorrhagic shock, acute single-organ or multiple-organ dysfunction, etc.); (11) Other factors deemed unsuitable for participation in this trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nutritional Indicators: Prognostic nutritional index (PNI) = serum albumin (g/L) +5× total peripheral blood lymphocytes (× 109/L);Inflammatory Indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nutritional Indicators: Serum albumin, prealbumin, transferrin, retinol-binding protein, nitrogen balance, Body mass index, triceps skinfold thickness and mid-upper arm muscle circumference;Immunological Indicators;Clinical Indicators;Recovery Indicators; | — |
Countries
China
Contacts
Public ContactZhou Wence
The Second Hospital of Lanzhou University
Outcome results
None listed